期刊文献+

RP-HPLC法测定人血浆中帕瑞昔布的浓度

Concentration Determination of Parecoxib in Human Plasma by RP-HPLC
原文传递
导出
摘要 目的:建立测定人血浆中帕瑞昔布的方法。方法:采用反相高效液相色谱法,血浆以无水乙醚提取后进样测定,色谱柱为KromasilC18,流动相为乙腈-水(92:8),内标为布洛芬,流速为1.0mL·min-1,检测波长为209nm,最小进样间隔为30min。结果:帕瑞昔布血药浓度在73.69~442.16μg·mL-1范围内线性关系良好(r=0.9992);方法回收率为97.26%~99.24%,提取回收率为79.27%~80.51%,日内和日间RSD均≤2.10%。结论:本方法简便、快速、准确、重复性好,可以满足帕瑞昔布血药浓度的测定要求。 OBJECTIVE:To develop a method for the concentration determination of parecoxib in human plasma.METHODS:RP-HPLC method was adopted.The plasma sample was extracted with absolute ether.The determination was performed on Kromasil-C18(250 nm×4.6 nm,5 μm)column with mobile phase consisted of acetontrile-water (92:8) at the flow rate of 1.0 mL·min-1.Ibuproren (IBF) was used as internal standard and UV detection wavelength was set at 209 nm.Minimum injection interval was 30 min.RESULTS:The linear range of parecoxib was 73.69~442.16 μg·mL-1(r=0.999 2).The method recovery was 97.26%~99.24% and extraction recovery was 79.27%~80.51%.The RSD of intra-day and inter-day were less than 2.10%.CONCLUSION:The method is simple,rapid,accurate,reproducible and suitable for the determination of parecoxib concentration in human plasma.
出处 《中国药房》 CAS CSCD 北大核心 2011年第18期1675-1677,共3页 China Pharmacy
关键词 反相高效液相色谱法 帕瑞昔布 血药浓度 药动学 RP-HPLC Parecoxib Plasma concentration Pharmacokinetics
  • 相关文献

参考文献6

二级参考文献18

  • 1Tallcy JJ, Bertenshaw SR, Brown DL, et al. N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt,parecoxib sodium: A potent and selective inhibitor of COX-2 forparenteral administration. J Med Chem, 2000;43:1661 - 1663. 被引量:1
  • 2Hubbard R, Kuss M, Talwalkers S, et al. Evaluation of parecoxib.A new injectable cycooxygense-2-specific inhibitor for the treatment of pain. Ann Emerg Med, 2000;36(Suppl):S69. 被引量:1
  • 3Cheer SM, Goa KL. Parecoxib (parecoxib sodium). Drugs, 2001;61:1133-41. 被引量:1
  • 4Karim A, Laurent A, Slater ME, et al. A pharmacokinetic study of intramuscular (i.m.) parecoxib sodium in normal subjects. J Clin Pharmacol, 2001;41:1111 -9. 被引量:1
  • 5Ibrahim A, Karim A, Feldman J,et al. The influence of parecoxib,a parenteral cyclooxygenase-2 specific inhibitor, on the pharmacokinetics and clinical effects of midazolam. Anesth Analg, 2002;95:667-73. 被引量:1
  • 6Barton SF, Langeland FF, Snabes MC, et aL Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology.2002;97:306-14. 被引量:1
  • 7Kenaan CA, Bikhazi GB, Deepika E, et al. Analgesic activity and safety of parecoxib in post-surgical patients: an interim report.Anesth Analg, 2001 ;92:$257. 被引量:1
  • 8Tang J, Li S, White PF, Chen X, et al. Effect of parecoxib, a novel intravenous cyclooxygenase type-2 inhibitor, on the postoperative opioid requirement and quality of pain control. Anesthesiology,2002;96:1305 - 9. 被引量:1
  • 9Rasmussen GL, Steckner K, Hogue C, et al. Intravenous parecoxib sodium foracute pain after orthopedic knee surgery. Am J Orthop,.2002;31:336--43. 被引量:1
  • 10Daniels SE, Grossman EH, Kuss ME, et al. A double-blind, randomized comparison of intramuscularly and intravenously administered parecoxib sodium versus ketorolac and placebo in a post-oral surgery pain model. Clin Ther, 2001 ;23:1018 - 31. 被引量:1

共引文献73

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部